Share price: 162.00p

Board Appointment

14th May 2013

Cello Group plc (AIM: CLL), the insight and strategic marketing group is pleased to announce the appointment of Stephen Highley to the Board as Group Corporate Development Director.

Stephen Highley is a co-founder of MSI, a strategy consulting firm acquired by Cello in 2007 and which is now a core component of Cello Health, the Group’s specialist healthcare division. Since 2012, Stephen  has also been Chairman of Cello Health.

Cello Group’s strategy is to expand through a mixture of accelerated organic growth and selected acquisition. As Group Corporate Development Director, Stephen will share responsibility for helping drive this process from a Board level.

Mark Scott, Cello CEO, commented; “We are delighted that Stephen is joining the Board at this time. The Group has a solid foundation from which to expand internationally in its chosen areas of focus, and Stephen will make a big difference to the rate at which we can achieve this.”

Under schedule 2, paragraph (g) of the AIM rules, the following additional information is disclosed:

–              Mr Highley has a beneficial interest in 2,000,868 ordinary shares of 10 pence each in the Company, which represents 2.42 per cent. of the Company’s current issued ordinary share capital.

–              Prior to his appointment to the board of the Group, Mr Highley did not hold any active directorships. Mr Highley has within the past 5 years been a director of MSI Consulting Ltd; Mash Health Ltd.

There are no other matters to be announced under paragraph (g) of Schedule 2 of the AIM Rules.



Cello Group plc 
Mark Scott, Chief Executive020 7812 8460
Mark Bentley, Group Finance Director 
Cenkos Securities plc 
Bobbie Hilliam020 7397 8927
Mark Edwards020 7466 5000
Sophie McNulty 
Clare Akhurst




Contact Us


Cello Health plc

Queens House

8-9 Queen Street



Registered Office

Queens House

8-9 Queen Street



Company Registered

in England no.05120150